Search | New Scientist

Is Alzheimer’s drug donanemab really a 'turning point' for treatment?

18 July 2023

The experimental drug donanemab slows the progression of Alzheimer's disease compared with a placebo, but the effect may not be large enough to be noticed by people with the condition or their families

Alzheimer's may be caused by the accumulation of protein plaques and tangles in the brain

Alzheimer's drug lecanemab slows cognitive decline but concerns linger

30 November 2022

The drug lecanemab slowed the rate of cognitive decline among people with early Alzheimer's disease by 27 per cent, compared with placebo infusions, but some question if its potential safety concerns outweigh any benefits

A species of the Trypanosoma brucei parasite, which can cause sleeping sickness, in blood

Drug clears sleeping sickness parasite from the body in clinical trial

29 November 2022

In a small trial, an experimental medicine was 100 per cent effective at ridding the parasite that causes sleeping sickness from the bodies of people with an early to intermediate infection

A person with diabetes injecting insulin

Drug that delays onset of type 1 diabetes gets approval in US

18 November 2022

In an ongoing trial, the drug teplizumab delayed the onset of type 1 diabetes in children and adults by nearly three years, compared with a placebo

An artificial intelligence could gauge how much pain a laboratory mouse is in based on its grimaces, potentially aiding the development of pain-relieving drugs

AI that can see pain in a mouse's face could aid drug development

1 September 2022

A new artificial intelligence that monitors mice grimaces to score their pain from 0 to 8 may help researchers judge the effectiveness of a new pain-relieving treatment

A 3D magnetic resonance imaging (MRI) scan of the brain of a 65-year-old after a stroke. The orange coloring represents an area of dead tissue

Stroke drug improves memory and repairs injured brain tissue in mice

28 July 2022

Unlike existing treatments that focus on rehabilitation or reducing the risk of an additional stroke, the experimental drug targets the "stickiness" that can prevent injured brain tissue from functioning as it should

Covid-19 news: Moderna’s omicron booster has promising immune response

9 June 2022

A regular round-up of the latest coronavirus news, plus insight, features and interviews from New Scientist about the covid-19 pandemic

Commuters at St Pancras International train station in London, England, in May

Covid-19 news archive: May 2022

6 June 2022

This is an archive of the New Scientist daily covid-19 news update: May 2022. Updates from: April 2022, March 2022, February 2022, January 2022, November/December 2021, September/ October 2021, July to September 2021, June/ July 2021, May 2021, March...

The Pfizer medicine Paxlovid can protect against severe covid-19 in vulnerable people

Covid-19 rebound seen in some people after taking Pfizer drug Paxlovid

18 May 2022

Pfizer’s Paxlovid can prevent severe covid-19 in vulnerable people when taken as a five-day course at home, but the medicine may not eradicate the virus in everyone

People queue for a PCR covid-19 test in Johannesburg, South Africa, on 30 November 2021

Covid-19 news archive: April 2022

8 May 2022

This is an archive of the New Scientist daily covid-19 news update: April 2022. Updates from: March 2022, February 2022, January 2022, November/December 2021, September/ October 2021, July to September 2021, June/ July 2021, May 2021, March 2021, February...